Skip to main content
MedPath Trial logoMedPath TrialMedPath Trial Home
Clinical Trials/EUCTR2010-019267-11-DE
EUCTR2010-019267-11-DEActive, not recruitingNot Applicable

AN OPEN-LABEL, MULTICENTER, RANDOMIZED, CROSS-OVER STUDY TO COMPARE THE SAFETY AND EFFICACY OF PANZYTRAT® 25 000 TO KREON® 25 000 IN THE CONTROL OF STEATORRHEA IN SUBJECTS AGED 7 YEARS AND OLDER WITH CYSTIC FIBROSIS (CF) AND EXOCRINE PANCREATIC INSUFFICIENCY (EPI)

Axcan Pharma Inc.0 sites68 target enrollmentStarted: October 19, 2010Last updated:
Share to TwitterShare to FacebookShare to LinkedInShare to Reddit
Conditions
Drugs

Trial Snapshot

Phase
Not Applicable
Status
Active, not recruiting
Sponsor
Enrollment
68
Study OverviewEligibility CriteriaInvestigatorsRecords & IdentifiersSimilar Trials

Study Overview

Brief Summary

No summary available.

Study Design

Study Type
Interventional clinical trial of medicinal product

Eligibility Criteria

Sex
All

Inclusion Criteria

  • •- After understanding the study procedures and agreeing to comply with the protocol, the subject or his/her legally authorized representative will sign an informed consent form (ICF) prior to starting any study procedures.
  • •- Subject has a diagnosis of CF that was based on one or more typical clinical features of CF phenotype, in addition to one of the following: a genotype that documents the presence of two (2) CF-causing mutation or a sweat chloride test = 60 mmol/L by quantitative pilocarpine iontophoresis on two separate occasions.
  • •- Male or female subjects aged 7 years or older.
  • •- Subject has a diagnosis of severe EPI confirmed by ELISA measurement of fecal elastase (FE-1) (test could have been performed in the past and result available). The severity of EPI will be defined by the laboratory according to their range. If EPI was never confirmed by FE-1 for a given subject, a stool sample will be collected prior to randomization and the result confirmed during the treatment phase.
  • •- Subject currently receives and had received a stable dose of lipase with either Panzytrat® 25 000 or Kreon® 25 000, for at least 30 days prior to ICF signature.
  • •- Subject is generally in good health, except for the underlying symptoms associated with CF and EPI and is clinically stable (no change in the last 30 days of physical examination) as evidenced by: medical and medication history, physical examination including vital signs during screening, and laboratory tests.
  • •- According to the qualification phase diary, subject will be able to maintain a CF standardized diet with a lipid content customized to his/her needs during the study.
  • •- Women of childbearing potential must have a negative pregnancy test at study entry and must use a medically acceptable contraceptive method for the duration of the study (i.e. from the qualification visit up to 30 days after the last study visit). Women who are not of childbearing potential will be defined as pre-menarcheal, post-menopausal (no presence of menses for at least 12 months if > 50 years of age, or no presence of menses for 24 months if = 50 years of age), surgically sterilized (tubal ligation for at least 6 months, ovariectomy or hysterectomy) or otherwise infertile.
  • •Are the trial subjects under 18? yes
  • •Number of subjects for this age range:
  • •F.1.2 Adults (18-64 years) yes
  • •F.1.2.1 Number of subjects for this age range
  • •F.1.3 Elderly (>=65 years) yes
  • •F.1.3.1 Number of subjects for this age range

Exclusion Criteria

  • •- Known contraindication, sensitivity or hypersensitivity to Panzytrat® 25 000 or Kreon® 25 000, or to any porcine protein.
  • •- Recent treatment of an emergent acute infection with oral or intravenous (IV) antibiotics that was not stopped at least 14 days prior to randomization.
  • •- Chronic use of narcotics that were not stopped at least 7 days prior to the qualification visit.
  • •- Use of any prohibited medications or products listed in the prohibited medication section of the protocol (see section 4.3.2)
  • •- History of significant bowel resection that could impair fat absorption. (N.B. Small bowel resection for meconium ileus at birth and appendectomy are acceptable.)
  • •- Presence of acute pancreatitis or exacerbation of chronic pancreatic disease
  • •- Presence of any significant gastrointestinal dysmotility disorders
  • •- Presence of chronic or severe abdominal pain
  • •- Use of enteral tube feeding over day and night
  • •- History or presence of clinically significant portal hypertension.
  • •- Presence of any condition known to increase fecal fat loss including but not limited to: celiac disease, Crohn's disease, tropical sprue, bacterial bowel infection, liver disease, lactose intolerance, pseudomembranous colitis, biliary and pancreatic cancer, radiation enteritis, Whipple’s disease, Whipple's procedure, etc.
  • •- Presence or history of complete Distal Intestinal Obstruction Syndrome (DIOS) in the past six (6) months, or two (2) or more incomplete DIOS in the past year, DIOS defined per the ESPGHAN criteria
  • •- Subject with poorly controlled diabetes as per the investigator’s opinion
  • •- Female subjects who are pregnant or breastfeeding
  • •- Presence of any condition or history of any illness, or pre-study laboratory abnormality which, in the opinion of the Investigator or sponsor, might put the subject at risk, prevent the subject from completing the study, or otherwise affect the outcome of the study.
  • •- Use of any investigational drug within 30 days prior to the date of signature of the ICF

Investigators

Sponsor
Axcan Pharma Inc.

Similar Trials

Completed
Phase 2
A RANDOMIZED, MULTICENTER, OPEN-LABEL CROSS-OVER STUDY TO EVALUATE PATIENT PREFERENCE AND SATISFACTION OF SUBCUTANEOUS ADMINISTRATION OF THE FIXED-DOSE COMBINATION OF PERTUZUMAB AND TRASTUZUMAB IN PATIENTS WITH HER2-POSITIVE EARLY BREAST CANCERThis study will evaluate patient preference for a subcutaneously administered fixed-dose combination formulation (FDC SC) of pertuzumab and trastuzumab compared with intravenously (IV) administered Perjeta® and Herceptin® formulations (P+H IV) in patients with HER2-positive (HER2+) early breast cancer (EBC). The study will also evaluate patient reported satisfaction with pertuzumab and trastuzumab FDC SC and health-related quality of life (HRQoL) outcomesHealthcare professionals (HCPs) perception of time/resource use and convenience of pertuzumab and trastuzumab FDC SC and P+H IVas well as the safety and efficacy of each study regimen.ABC
LBCTR2019030205F. HOFFMANN-LA ROCHE LTD140
Active, not recruiting
Phase 1
A Study to Evaluate Participant and Healthcare Professional Reported Preference for Subcutaneous Atezolizumab Compared with Intravenous Atezolizumab Formulation in Participants with Non-Small Cell Lung Canceron-Small Cell Lung Cancer (NSCLC)MedDRA version: 21.1Level: PTClassification code 10061873Term: Non-small cell lung cancerSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)
EUCTR2021-004067-28-ITF. HOFFMANN - LA ROCHE LTD.140
Active, not recruiting
Phase 1
A Study to Evaluate Participant and Healthcare Professional Reported Preference for Subcutaneous Atezolizumab Compared with Intravenous Atezolizumab Formulation in Participants with Non-Small Cell Lung Cancer
EUCTR2021-004067-28-FIF. Hoffmann-La Roche Ltd175
Completed
Phase 2
A Study to Evaluate Patient Preference and Satisfaction of Subcutaneous Administration of the Fixed-Dose Combination of Pertuzumab and Trastuzumab in Participants With HER2-Positive Early Breast CancerHER2-Positive Early Breast CancerBreast NeoplasmsBreast DiseasesSkin DiseasesSkin and Connective Tissue Diseases
RPCEC00000299Roche Servicios S.A.
Active, not recruiting
Phase 1
A Study to Evaluate Participant and Healthcare Professional Reported Preference for Subcutaneous Atezolizumab Compared with Intravenous Atezolizumab Formulation in Participants with Non-Small Cell Lung Canceron-Small Cell Lung Cancer (NSCLC)MedDRA version: 21.1Level: PTClassification code 10061873Term: Non-small cell lung cancerSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)
EUCTR2021-004067-28-ESRoche Farma S. A. U. que realiza el ensayo en España y que actúa como representante F. Hoffmann-La Roche Ltd140